This interactive and fast-paced activity will test your knowledge and practice with multiple choice questions and patient case vignettes. You will learn what the expert has to say about treatment approaches in moderate-to-severe and difficult-to-treat pediatric asthma, as well as have the opportunity to compare yourself to your peers.
This interactive slide-audio activity is based on symposia proceedings from the 2017 Fall Clinical Dermatology Conference, the Winter Clinical Dermatology Conference, and the Pacific Dermatologic Association Annual Meeting. The program will discuss these issues and utilize patient cases to provide insights and context.
In this case-based educational program, you will meet 3 patients in an AD clinic, make management decisions, compare your responses with those of your peers, and learn from the experts about best management approaches.
The common misconception in atopic dermatitis (AD) is that it is a limited, site-specific skin disease rather than a systemic disorder. This can lead to ineffective treatment selection amid the increasingly complex clinical landscape of systemic management of AD. This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient care to allow you to rethink clinical decisions based on the scenarios presented, and to modify treatment plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.
In preparation for an archived webinar, you will complete this self-study module which includes case reviews and the opportunities to pose questions and interact with faculty members.
This interactive and fast-paced activity will allow you to test your knowledge and practice via a series of multiple choice questions. The program includes case vignettes, an opportunity to test your knowledge against your peers, and expert guidance about treatment approaches in HER2-postive breast cancer.
Chronic Lymphocytic Leukemia
Along with the rest of the oncology field, the management of CLL is experiencing a paradigm shift toward targeted therapy and personalized medicine. This interactive, fast-paced activity will allow you to examine your knowledge and practice skills via questions and case vignettes. You will have the opportunity to compare yourself to your peers and receive expert guidance on the successful management of chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world.
Designed for researchers in hematology/oncology and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies, this program provides cutting-edge research about newly approved and emerging treatments for leukemia, lymphoma, and myeloma.
Based on the proceedings from a live continuing medical education series, this interactive multichallenge activity will discuss issues and updates in hereditary angioedema (HAE). Faculty experts provide commentary on the newest developments in HAE while patient case challenges test your knowledge and skill in diagnosing and treating HAE.
This activity calls upon experts to provide evidence-based support and clinical rationale for using PCSK9 inhibitors when treating patients with hypercholesterolemia. Participants will complete interactive case challenges to learn about patient eligibility and required documentation for payers via the use of clinical trial and tolerability data.
This activity provides evidence-based support and clinical rationale for incorporating PCSK9 inhibitors into the treatment of patients with hypercholesterolemia. Through interactive case challenges, participants will understand patient eligibility and required documentation for payers, using clinical trial and tolerability data.
Inflammatory Bowel Diseases
This Clinical Convergence® activity is unique in its integration of healthcare provider and patient perspectives. It includes clinical content that zeroes in on certain aspects of inflammatory bowel disease (IBD) care, such as personalized treatment decisions, patient/drug monitoring, and shared decision making.
This case-based activity for physicians, gastroenterologists, nurse practitioners, and physician assistants presents a patient whose symptoms are consistent with inflammatory bowel disease (IBD). Participants are able to virtually diagnose, treat, and manage the patient while learning from expert faculty.
This activity helps physicians, gastroenterologists, nurse practitioners, and physician assistants choose acute and long-term medical therapy for inflammatory bowel disease (IBD) and decide when surgery is indicated.
This activity explores the Crohn's & Colitis Foundation's IBD Nutrition Care Pathway with 2 video segments in which a physician, a dietitian, and a patient with IBD discuss malnutition.
The IBD Nutrition Care Pathway from the Crohn's and Colitis Foundation is beneficial in the screening, evaluation, intervention, and follow-up of IBD patients and patients with malnutrition. This activity will provide education on the application of key elements of this pathway, as well as 2 video segments of panel discussions between a physician, a dietitian, and a patient with IBD.
This activity is intended for gastroenterologists, gastroenterology nurse practitioners, and PAs who actively manage patients with inflammatory bowel disease (IBD), as well as managed care directors and hospital pharmacists interested in IBD treatment options.
Metastatic Gastric Cancer
In this interactive activity you will receive updates on recent developments in gastric/GEJ cancer treatment, as well as the opportunity to compare your question responses to those of your peers.
Non-Small Cell Lung Cancer
A QI project on quality measures in the treatment of advanced NSCLC has been initiated by Cancer Care Partners, a virtual oncology clinic system. In this program, the QI team's progress will be reviewed, and participants will have the opportunity to interact with them as the QI initiative progresses.
Solid Organ Transplant
This article reviews the pathophysiology of antibody‐mediated rejection (AMR) and the required features for a definitive diagnosis of AMR according to the latest Banff criteria. Clinical data on current and investigational treatments are summarized, strategies to improve outcomes are presented, and a discussion of relevant predictive and surrogate endpoints provides a framework for future studies.